Pacific Biosciences of California Inc
NASDAQ:PACB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (3.6), the stock would be worth $0.06 (96% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 86.7 | $1.54 |
0%
|
| 3-Year Average | 3.6 | $0.06 |
-96%
|
| 5-Year Average | 3.7 | $0.07 |
-96%
|
| Industry Average | 4.3 | $0.08 |
-95%
|
| Country Average | 2.5 | $0.04 |
-97%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Pacific Biosciences of California Inc
NASDAQ:PACB
|
471.1m USD | 86.7 | -0.8 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
962.6B USD | 132.8 | 3 990.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.6B USD | 3.3 | 25.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 2.4 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.6B CNY | 3.7 | 15.5 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 3.9 | -122.9 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.7 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 11.5 | 45.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 4.3 | 20.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | -1 098.4 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Pacific Biosciences of California Inc
Glance View
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 728 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The firm has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include Sequel, Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together can sequence up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together conduct, monitor, and analyze single molecule biochemical reactions in real time. The firm's Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.
